Attached files
| file | filename |
|---|---|
| EX-10.2 - EX-10.2 - Intersect ENT, Inc. | d332452dex102.htm |
| EX-10.1 - EX-10.1 - Intersect ENT, Inc. | d332452dex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 18, 2017
Intersect ENT, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36545 | 20-0280837 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Intersect ENT, Inc.
1555 Adams Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)
(650) 641-2100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(e)
2017 Salary Increases, Option Grants and Bonus Plan for Named Executive Officers
On January 18, 2017, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Intersect ENT, Inc. (the “Company”) approved annual salaries, stock option awards, restricted stock units and target bonus percentages for 2017 for the Company’s Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Vice President of Clinical Affairs, each a “Named Executive Officer” (as defined under applicable securities laws). The 2017 compensation information for such executive officers is set forth on Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
The Compensation Committee also approved the form of restricted stock unit award agreement, a copy of which is filed hereto as Exhibit 10.2. All restricted stock unit awards granted by the company shall be subject to the terms and conditions substantially in the form set forth in this form of restricted stock unit award agreement.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 10.1 | 2017 Named Executive Officer Compensation. | |
| 10.2 | Form of Restricted Stock Unit Award Agreement under the 2014 Equity Incentive Plan. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Intersect ENT, Inc. | ||||||
| Dated: January 20, 2017 | ||||||
| By: | /s/ Jeryl L. Hilleman | |||||
| Jeryl L. Hilleman | ||||||
| Chief Financial Officer | ||||||
INDEX TO EXHIBITS
| Exhibit No. |
Description | |
| 10.1 | 2017 Named Executive Officer Compensation. | |
| 10.2 | Form of Restricted Stock Unit Award Agreement under the 2014 Equity Incentive Plan. | |